| Name | Title | Contact Details |
|---|
Partner Therapeutics is devoted to developing and commercializing cancer medicines and combination therapies that can make a meaningful difference in the lives of cancer patients.
Precision IBD, Inc. is a biopharmaceutical company focused on the discovery an development of a broad portfolio of precision therapeutics and companion diagnostics for inflammatory bowel disease.
Celtaxsys is a privately-held clinical stage drug discovery and development company with operations in San Francisco, CA and Atlanta, GA.
Rakuten Medical, Inc. is a global clinical stage biotechnology company developing and commercializing precision, cell-targeting investigational therapies on its IlluminoxTM platform, which, in pre-clinical studies have been shown to induce rapid and selective cell killing and tumor necrosis. Outside of Japan, Illuminox therapies have not yet been approved as safe or effective by any regulatory authority. The company`s first drug developed on the Illuminox platform, ASP-1929, has received approval from the Japanese Ministry of Health, Labour, and Welfare, and is currently the subject of a global phase 3 clinical trial for recurrent head and neck cancer. Rakuten Medical is committed to its mission to conquer cancer and aims to realize a society where cancer patients can lead fulfilling lives. The company has 6 locations in 5 countries, including the United States, where it is headquartered, Japan, the Netherlands, Taiwan, and Switzerland.
Mitsubishi Tanabe Pharma Development America is a Warren, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.